ArticleAntimicrobial agents and chemotherapy1998
Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression.
Article in Antimicrobial agents and chemotherapy, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 88 citations in OpenAlex.
- Antifungal treatment strategies and their impact on resistance development in clinical settings.The Journal of antimicrobial chemotherapy · 2025Review
- Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.Acta pharmaceutica Sinica. B · 2025Review
- The Host Immune Response toJournal of fungi (Basel, Switzerland) · 2021Review
- Therapeutic effects of pentoxifylline on invasive pulmonary aspergillosis in immunosuppressed mice.BMC pulmonary medicine · 2021Article
- Immunomodulation for the Treatment of Fungal Infections: Opportunities and Challenges.Frontiers in cellular and infection microbiology · 2020Review
- Animal Models of Aspergillosis.Comparative medicine · 2018Review
- Rodent Models of Invasive Aspergillosis due toFrontiers in microbiology · 2017Review
- Nebulised amphotericin B-polymethacrylic acid nanoparticle prophylaxis prevents invasive aspergillosis.Nanomedicine : nanotechnology, biology, and medicine · 2015Article
- Experimental therapy with azoles against Candida guilliermondii.Antimicrobial agents and chemotherapy · 2014Article
- Treatment options in Invasive Aspergillosis.Current treatment options in infectious diseases · 2014Article
- Inflammatory cells' role in acetic acid-induced colitis.Advanced biomedical research · 2014Article
- Anidulafungin in treatment of experimental invasive infection by Candida parapsilosis: in vitro activity, (1-->3)-beta-D-glucan and mannan serum levels, histopathological findings, and in vivo efficacy.Antimicrobial agents and chemotherapy · 2011Article
- Combined therapy against murine-disseminated infection by Fusarium verticillioides.Mycopathologia · 2011Article
- Immunomodulation Therapy for Invasive Aspergillosis: Discussion on Myeloid Growth Factors, Recombinant Cytokines, and Antifungal Drug Immune Modulation.Current fungal infection reports · 2010Article
- Host immune response against Scedosporium species.Medical mycology · 2009Review
- Combined therapies in a murine model of blastoschizomycosis.Antimicrobial agents and chemotherapy · 2007Article
- Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis.Infection and immunity · 2005Article
- Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans.Antimicrobial agents and chemotherapy · 2004Article
- Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis.Antimicrobial agents and chemotherapy · 2004Article
- Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum.Antimicrobial agents and chemotherapy · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Outbred ICR mice were immune suppressed either with hydrocortisone or with 5-fluorouracil and were infected intranasally with Aspergillus fumigatus. Beginning 3 days before infection some groups of mice were given recombinant human granulocyte colony-stimulating factor (G-CSF), SCH56592 (an antifungal triazole), or both. Corticosteroid-pretreated mice responded to SCH56592 and had reduced counts in lung tissue and prolonged survival. In these mice, G-CSF strongly antagonized the antifungal activity of SCH56592. Animals treated with both agents developed large lung abscesses with polymorphonuclear leukocytes and large amounts of Aspergillus. In contrast, mice made neutropenic with 5-fluorouracil and then infected with A. fumigatus conidia benefited from either G-CSF or triazoles, and the effect of the combination was additive rather than antagonistic. Host predisposing factors contribute in different ways to the outcome of growth factor therapy in aspergillosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.